Immunotherapy for early rectal cancer with dMMR or MSI
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether immunotherapy (nivolumab plus ipilimumab) can help people with early-stage rectal cancer that has dMMR or MSI changes. It’s meant for patients who have not yet had chemotherapy, radiation, or immunotherapy for colorectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (age 18 or older).
- Have non-metastatic rectal cancer in stage 1, 2, or 3, confirmed by tissue testing.
- Your tumor must be dMMR or MSI (a lab test on the cancer tissue).
- You should not need local treatment like TEM (a procedure for some early rectal cancers).
- You must be healthy enough for treatment: good blood counts (neutrophils and platelets) and kidney/liver function.
- You must not have had chemotherapy, radiation, or immunotherapy for colorectal cancer before starting this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
This study tests a combination of internal radiation therapy (brachytherapy) followed by an immunotherapy drug (nivolumab) before surgery for rectal cancer. The goal is to see if this approach can shrink the tumor more and improve outcomes.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
Hear when a new Cancer of Rectum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.